TokenPost·

Lexeo Trial Data Leads Raymond James and Cantor Fitzgerald to Raise Targets

Your call?

The target changes followed interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. Raymond James views Lexeo as a strong buy.

Share

More news